Zoetis Inc. (ZTS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 6,675 | 7,776 | 8,080 | 8,544 | 9,256 | 9,467 | 9,517 | 9,286 |
| Operating profit | $m | 3,597 | 3,521 | ||||||
| Net profit | $m | 1,638 | 2,037 | 2,114 | 2,344 | 2,486 | 2,673 | 2,616 | 2,782 |
| EPS reported | $ | 6.02 | 6.07 | ||||||
| Operating cashflow per share | $ | 6.55 | 6.91 | ||||||
| Capex per share | $ | 1.40 | 1.25 | ||||||
| FCF per share | $ | 5.15 | 5.67 | ||||||
| Free cash flow | $m | 2,283 | 2,366 | ||||||
| Net debt | $m | 6,979 | 7,372 | ||||||
| Book value equity | $m | 3,331 | 3,148 | ||||||
| Book value per share | $ | 7.51 | 7.54 | ||||||
| Number of shares | m | 443.84 | 417.7 | ||||||
| DPS (TTM paid) | $ | 2.00 | 2.09 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 20.90 | 11.71 | ||||||
| P/B LTM | x | 16.75 | 17.72 | ||||||
| P/S LTM | x | 5.89 | 5.86 | ||||||
| P/FCF LTM | x | 24.44 | 23.58 | ||||||
| EV/EBITDA LTM | x | 15.48 | 16.26 | ||||||
| EV/Sales LTM | x | 6.65 | 3.16 | ||||||
| Earnings Yield LTM | % | +4.78% | +8.54% | ||||||
| FCF Yield | % | +4.09% | +4.24% | ||||||
| Quality | |||||||||
| ROE | % | +80.25% | +69.25% | ||||||
| ROIC | % | +21.54% | +21.63% | ||||||
| Operating margin | % | +38.00% | +37.00% | ||||||
| Gross margin | % | +70.49% | +70.87% | ||||||
| FCF/Sales | % | +24.12% | +24.86% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +10.05% | +10.97% | ||||||
| Sales Growth YoY | % | +2.28% | +2.82% | ||||||
| Net Income Growth YoY | % | +7.52% | +5.23% | ||||||
| FCF Growth | % | -0.65% | +2.96% | ||||||
| Operating Profit Growth | % | +6.04% | +3.80% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.59% | +2.80% | ||||||
| Dividend Growth | % | +15.74% | +20.95% | ||||||
| Payout Ratio | % | +33.27% | +34.02% | ||||||
| FCF/Debt | x | 0.24 | 0.26 | ||||||
| Net Debt/EBITDA | x | 1.76 | -0.33 | ||||||
| EBIT/Net interest | x | 14.80 | 14.43 | ||||||
| Net debt/market cap | % | +16.65% | +0.61% | ||||||
| Net debt/Equity | x | 2.10 | 2.34 | ||||||
| Gross debt/equity | x | 2.85 | 2.93 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free